☆ 4.6 Meeting Abstract

HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy

JOURNAL OF THORACIC ONCOLOGY (2021)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 16, Issue 3, Pages S118-S119

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2021.01.299

Keywords

HUDSON; Durvalumab; platform study

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.